Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model, page-48

Another thing to note, with Carfilzomib patent protection expiring in 2027, it's possibly not only Amgen that could see value in these results.

Whilst Amgen may currently have the most to gain from a Carfilzomib/Bisantrene combination in terms of protecting their revenue stream, come 2027 another party could potentially pursue a combination of generic Carfilzomib and Bisantrene should a favourable deal with Amgen not eventuate.

This, as well as the timeframe, should at least help put some pressure on Amgen as it means Race isn't necessarily in a "take it or leave it" situation with them.

With RC220 on the verge of hitting the clinic, hopefully Race can begin to convert some of these pre-clinical synergies into something much more material in nature. There's too much work to do to here for Race to go it alone on everything.